Dividends Inside 
AbbVie Inc.
ABBV
$250.40 (+ $0.94 + 0.38%)
Last updated: 2026-08-17 23:04 UTC
AbbVie Inc. trades under ticker ABBV on NYSE as a stock. Use this page to review stock price, share price, dividends, and price history. The page also shows Healthcare exposure. Identifiers: ISIN US00287Y1091, CUSIP 00287Y109. Also searched as AbbVie.
Related researchABBV stock priceABBV share priceABBV dividend historyABBV dividend yieldAbbVie dividend historyAbbVie dividend yield00287Y109AbbVie stockAbbVie share price
About the Company
AbbVie Inc. is a global biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing medicines and therapies for complex and serious diseases. AbbVie’s current portfolio spans immunology, oncology, neuroscience, eye care, and aesthetics, with additional products in virology, gastroenterology, and other specialty areas. The company serves patients through prescription medicines and advanced therapies used in rheumatology, dermatology, gastroenterology, blood cancers, migraine, psychiatric disorders, eye conditions, and certain chronic infectious diseases. AbbVie also markets products through its Allergan Aesthetics business, giving it a presence in both therapeutic healthcare and medical aesthetics. Headquartered in North Chicago, Illinois, AbbVie plays a significant role in the global pharmaceutical market by combining research, manufacturing, and commercialization across multiple high-value specialty segments.
Price History
Latest News for ABBV
Jim Cramer Reveals AbbVie’s (ABBV) “Good Stuff”
We recently published Jim Cramer Revealed His Big AI Investing Fear & Discussed These 20 Stocks. AbbVie Inc. (NYSE:ABBV) is one of the stocks discussed by Jim Cramer. Pharmaceutical firm AbbVie Inc. (NYSE:ABBV)’s shares are up by 11% over the past year and are down by 9% year-to-date. Evercore ISI was out with optimistic coverage […]
2 Cash-Producing Stocks to Research Further and 1 We Find Risky
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
The Zacks Analyst Blog NVIDIA, Mastercard, AbbVie, Waterstone and Precipio
AI demand and pipeline growth headline top Zacks stock reports on NVIDIA, Mastercard and AbbVie.
A Look At AbbVie (ABBV) Valuation After New Immunology Data And Upgraded 2026 Earnings Outlook
AbbVie (ABBV) is back in focus after presenting fresh real world and long term data for its key immunology drugs SKYRIZI and RINVOQ at the 2026 Digestive Disease Week meeting. See our latest analysis for AbbVie. Those fresh immunology data and a string of recent conference appearances come as AbbVie’s share price has eased this year, with a year to date share price return of down 9.35%, even though the 1 year total shareholder return is 14.17% and the 5 year total shareholder return is...
Why AbbVie Inc. (ABBV) is One of the Best Healthcare Stocks to Buy for the Long Term
AbbVie Inc. (NYSE:ABBV) is one of the best healthcare stocks to buy for the long term. AbbVie Inc. (NYSE:ABBV) received a rating update from Evercore ISI on May 4, with the firm lifting the price target on the stock to $236 from $232 while maintaining an Outperform rating on the shares. The company also announced […]
Top Stock Reports for NVIDIA, Mastercard & AbbVie
NVIDIA, Mastercard and AbbVie headline Zacks' top stock reports, with AI growth, payment trends and drug launches in focus.